We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (DKK)276.76−6.12 (−2.16%)as of 17 Nov 2026
Funds that hold it9One fund per scheme
Held through a master fund90 buy the stock themselves
Largest weight in a single fund2.45%Of that fund's NAV
Median weight2.40%Half the funds hold more than this
What does NVO do
Novo Nordisk A/S
A Danish drug company that leads in diabetes and obesity treatments such as insulin and GLP-1 drugs; its main revenue is sales of these drugs worldwide
OzempicWegovyRybelsusTresibaNovoRapid
Where the revenue comes from, and how much is left as profit (FY2025)
For every 100 DKK of sales: cost of sales 19 · operating expenses 40 · tax and other items 8 · leaving 33 as net profit
Which funds let you invest in NVO
Sorted by weight held, largest first
Investors in Thailand can buy NVO through 9 mutual funds open to retail investors. Most of them (9 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds NVO.
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
How Thai money reaches NVO
2 master funds
Master fund
Thai funds using this route
Master fund's NVO weight
JPMorgan Funds - Global Healthcare Fund
6
2.41%
JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD
3
2.45%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Revenue by business segment: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
Via JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD
+20.83%
Showing 9 of 9 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
Valuation and key ratios
Novo Nordisk A/S · NYSE · ราคาแปลงจาก NVO (USD) · Fiscal year ends in January
Market cap1.2T DKK4.47 billion shares
P/E12.0xPrice ÷ FY2025 EPS 23.03
Forward P/E12.6xBased on forecast 12-month earnings
P/S3.7x
EV/EBITDA7.8x
Dividend yield4.56%12.61 DKK per share a year
ROE60.7%Net profit ÷ shareholders' equity
Debt to equity (D/E)1.36xInterest-bearing debt
Beta0.70Against the S&P 500
Gross margin81.0%FY2025
Operating margin41.3%FY2025
Net margin33.1%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth21.7%Fast growth
Yearly average over the last 4 years · Latest annual sales 309.1B DKK
Profit from sales33%Highly profitable
For every 100 DKK of sales, about 33 DKK is left as net profit
Dividend4.56%Pays dividends
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price−16.0%Down
Now 36.4% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 21.7% a year on average · EPS grows 22.1% a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY2021140.8B DKK47.8B DKK
FY2022177.0B DKK55.5B DKK
FY2023232.3B DKK83.7B DKK
FY2024290.4B DKK101.0B DKK
FY2025309.1B DKK102.4B DKK
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q3 FY202575.0B DKK20.0B DKK
Q4 FY202579.1B DKK26.9B DKK
Q1 FY202696.8B DKK48.6B DKK
Q2 FY202678.5B DKK21.0B DKK
Q3 FY202679.2B DKK16.7B DKK
Annual income statement, balance sheet and cash flow
Item (DKK)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
140.8B DKK
177.0B DKK
232.3B DKK
290.4B DKK
309.1B DKK
Gross profit
117.1B DKK
148.5B DKK
196.5B DKK
245.9B DKK
250.3B DKK
Operating profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 276.76 DKK on 17 Nov 2026
Daily trendLeaning upScore 0.30 on a scale of −1 to +1 · 1254 bars
RSI(14)
52.1
ADX(14)
33.4
Position in the price range
30%
Weekly trendClear downtrendScore −0.90 on a scale of −1 to +1 · 262 bars
RSI(14)
43.6
ADX(14)
14.4
Position in the price range
19%
Monthly trendClear downtrendScore −1.00 on a scale of −1 to +1 · 61 bars
RSI(14)
37.4
ADX(14)
24.1
Position in the price range
5%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
279.17
277.83
Below
20 days
273.34
274.94
Above
50 days
271.30
277.90
Above
100 days
298.27
287.53
Below
Indicators (daily)
Indicator
Value
Signal
RSI(14)
52.07
Up
MACD(12,26)
2.71
Up
ADX(14)
33.43
Neutral
ATR(14) % of price
1.58
Neutral
Support and resistance (weekly pivots)
s3268
s2271
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
JPMorgan Funds – Global Healthcare Fund, Class A (acc) - USD
+20.83%
1.76%
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in NVO, not the look-through weight · Past performance is not a guarantee of future performance